- Home
- HURA vs GNLX Comparison
HURA vs GNLX Comparison
Compare HURA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- GNLX
- Stock Information
- Founded
- HURA 2009
- GNLX 2001
- Country
- HURA United States
- GNLX United States
- Employees
- HURA N/A
- GNLX N/A
- Industry
- HURA
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- HURA
- GNLX Health Care
- Exchange
- HURA Nasdaq
- GNLX Nasdaq
- Market Cap
- HURA 103.3M
- GNLX 109.4M
- IPO Year
- HURA N/A
- GNLX 2023
- Fundamental
- Price
- HURA $2.33
- GNLX $3.38
- Analyst Decision
- HURA Strong Buy
- GNLX Strong Buy
- Analyst Count
- HURA 2
- GNLX 4
- Target Price
- HURA $11.50
- GNLX $17.75
- AVG Volume (30 Days)
- HURA 475.4K
- GNLX 152.0K
- Earning Date
- HURA 08-15-2025
- GNLX 08-13-2025
- Dividend Yield
- HURA N/A
- GNLX N/A
- EPS Growth
- HURA N/A
- GNLX N/A
- EPS
- HURA N/A
- GNLX N/A
- Revenue
- HURA N/A
- GNLX N/A
- Revenue This Year
- HURA N/A
- GNLX N/A
- Revenue Next Year
- HURA $69.15
- GNLX N/A
- P/E Ratio
- HURA N/A
- GNLX N/A
- Revenue Growth
- HURA N/A
- GNLX N/A
- 52 Week Low
- HURA $1.80
- GNLX $1.60
- 52 Week High
- HURA $10.49
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- GNLX 63.14
- Support Level
- HURA N/A
- GNLX $2.80
- Resistance Level
- HURA N/A
- GNLX $3.61
- Average True Range (ATR)
- HURA 0.00
- GNLX 0.21
- MACD
- HURA 0.00
- GNLX 0.05
- Stochastic Oscillator
- HURA 0.00
- GNLX 73.26
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.